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Abstract
Background: Within the United States, chronic disease in children has doubled over the last 20
years. Many diseases defined as chronic (attention deficit, epilepsy, and diabetes) require daily
medication regimens for optimal management. To be covered by insurance, many of these
medications require prior authorization (PA) from the patients’ pharmacy benefits policy. Delays
in processing and receiving PA orders can lead to worsening disease and inadequate disease
management.
In 2014, a pediatric academic medical center in the Midwest found that processing
medications from prescription order to PA approval took nurses an average of over 90 hours. In
August 2020, the organization implemented an electronic prior authorization (ePA) system that
interfaced with the organization’s electronic health record (EHR). The primary goals of this
implementation were to reduce medication PA turnaround times and to increase employee
engagement with the ePA system.
The goals of this quality improvement (QI) project are to optimize the existing ePA
system with the medication PA process to reduce average medication PA turnaround times and
to increase the approval rates for medication PAs by five percent.
Project Design: Three interventions support the outputs of this QI project.
1. Increase the availability of the ePA system by changing the patient and pharmacy
benefits insurance matching interface logic.
2. Reduce the number of medications falsely requiring PA by removing them from the ePA
system.
3. Increase PA processing efficiency by improving the workflow for attaching documents
required for PA approval.
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To accomplish and measure these interventions, data reports and surveys were developed to
establish baselines and to measure ePA turnaround times, PA approval rates, and user
satisfaction both pre- and post-intervention. User satisfaction was measured utilizing a secure
online survey emailed to ambulatory division nurses.
Results: The median medication ePA turnaround pre- and post-interventions was unchanged at
36 hours. The ePA approval percentage dropped from 55.7% in June 2021 to 46.9% in August
2021. The primary QI project outcomes of reducing turnaround time and increasing the approval
rate by 5% were not met. A user involvement survey was sent to 194 nurses with a response rate
of 29% pre intervention and 8% post intervention. Overall user satisfaction was measured using
a net promotor score which registered scores of –70 pre- and –82 post-intervention, revealing
overall dissatisfaction with the ePA system. The use of an alternative ePA system outside the
organization’s EHR was discovered after the QI project data was reviewed and showed that
roughly 45% of ePAs were completed using this alternative system during the QI project
timeframe.
Recommendations: User involvement surveys measure user engagement with electronic systems
and measuring user satisfaction is beneficial to providing direction for interventions as well as
predicting future utilization of healthcare informatics projects.
Conclusion: Though most of the goals for this QI project outcome were not met, use of the
alternative ePA system confirmed the Technology Acceptance Model that users prefer the
electronic system that they perceive as being the most useful. Nurses using ePA will use the
system that best addresses their own user experiences regarding content, accuracy, format,
timeliness, ease of use, and overall satisfaction.
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Optimizing Electronic Medication Prior Authorization: Reducing Prescription Delays

Patients who are prescribed medications requiring pharmacy benefits prior authorization
(PA) often experience delays in receiving them. These delays result in worsening disease status
and inadequate disease management (Bergeson et al., 2013; Dunn et al., 2017). To reduce PA
medication delays, this pediatric organization in the Midwest implemented an electronic
medication prior authorization (ePA) system that interfaced with the organization’s electronic
health record (EHR) system, thus safely automating communication between the ordering
provider and the patients’ pharmacy benefits manager. This quality improvement (QI) project
optimizes and evaluates the ePA application program interface (ePA API) with the medication
PA process through specifically designed interventions in order to reduce medication PA
turnaround times, increase employee engagement with the ePA system, and better serve the
pediatric population in management of various chronic diseases such as diabetes, ADHD, and
epilepsy.
Background
The Centers for Disease Control (CDC) defines chronic diseases as health conditions
requiring ongoing medical attention, limiting activities for daily living, and lasting more than a
year (2020). In the United States, the number of children with chronic disease has dramatically
increased from 12.8% in 1994 to 26.6% in 2006 (Van Cleave et al., 2010). Juvenile diabetes
increased 23% between 2001 and 2009 (Van Cleave et al., 2010). In 2015, epilepsy affected
479,000 children in the United States, which is roughly 1 in 20 children (Zack & Kobau, 2015).
Attention deficit and hyperactivity disorders (ADHD) is one of the most common
neurodevelopmental disorders in childhood and in 2011, it affected 1 in 10 children ([Attention-
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deficit/hyperactivity Disorder (ADHD]), n.d.). As chronic diseases, diabetes, epilepsy, and
ADHD have treatment medications, most requiring prior authorization from the patient’s
pharmacy benefits plan in order to be fully covered by insurance.
These PAs are required by health care insurance companies for many reasons, but
primarily to minimize costs through reducing duplication, to ensure the medications are
medically necessary, and to encourage less expensive alternative medications if possible.
Medications requiring PA have increased from 8% to approximately 24% of covered drugs on
Medicare Part D plans between 2007 and 2019 (Resnick, 2020). In four therapeutic classes, the
number of steps required to obtain medication PA doubled in 5 years between 2011 and 2016
(Resnick, 2020). Though Medicare Part D primarily provides pharmacy benefits for patients over
the age of 65, the state of Illinois’ Medicaid pharmacy benefits insurance and formulary closely
aligns with it. At the pediatric organization, approximately 54% of patients are covered by
Illinois Medicaid or Medicaid Managed Care Organizations. Children with chronic diseases such
as diabetes, epilepsy, attention deficit and hyperactivity (ADHD), and asthma require daily
medications for proper disease management and to prevent clinical crises such as diabetic
ketoacidosis, psychiatric emergencies, asthma exacerbations, and seizures. Requiring medication
PA subjects these patients to immediate time delays as medications are held pending verification
or denial of insurance coverage. These delays result in worsening disease status and inadequate
disease management (Bergeson et al., 2013; Dunn et al., 2017).
Local Problem
Delays and denials in receiving medications can result in significant morbidity and
mortality for pediatric patients with chronic diseases.
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For example, critical diabetes medications such as insulin, metformin, and sodium
glucose inhibitors, along with the glucometers and supplies necessary to administer and monitor
the disease, require medication PA from most healthcare insurers.
Diabetes is the second most common chronic disease in the Chicago pediatric population.
In Chicago, the incidence of diabetes in “individuals <18 years of age increased 2.7% per annum
between 1994 and 2003” (Estrada, Danielson, Drum, & Lipton, 2009). At the pediatric
organization, the rate of newly diagnosed type 2 diabetes has tripled since 2012, matching the
rate increase found in the United States. In North America, the incidence of Type 2 diabetes
mellitus “now accounts for about 15% to 45% of all newly diagnosed cases of diabetes in
children and teenagers” (Fagot-Campagna et al., 2000, p. 668). Along with the increased rate of
newly diagnosed type 2 diabetes, Chicago youth have experienced a tripling of obesity rates
(Reinehr, 2013). A 2019 Community Health Needs Assessment from the pediatric organization
lists chronic disease as one of four health priorities needing to be addressed with a strategic plan
(“Community Health Needs Assessment,” 2019, p. 5). This population health data clearly reveals
that the prevalence, incidence, and morbidity and mortality of diabetes is increasing, and proper
disease management should be a priority for achieving improved health within the pediatric
population.
In 2015, the pediatric organization ambulatory leaders completed a performance
improvement assessment requiring nursing staff to manually track the amount of time it took for
prescriptions requiring PA in seven ambulatory specialties to be filled/approved? When
measured from EHR order to PA approval time, the data revealed that it took an average of over
90 hours for medications requiring PA to be approved. The assessment also found that full-time
nurses spent an average of 5 hours per week processing medication PAs, including phone calls,
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faxes, emails, and navigation of pharmacy insurance portals. Ambulatory nurses considered this
time administrative work and voiced their dissatisfaction with specific comments in the pediatric
organizations 2018 employee engagement survey. Time spent processing PAs could instead be
spent on primary ambulatory care nursing responsibilities such as coordinating patient care,
providing patient education, managing medications, and providing direct clinical care.
In addition to nursing, other healthcare professionals such as pharmacists, medical
assistants, physicians, and advanced practice providers participate in or perform the medication
PAs, spending equivalent amounts of time doing so. According to an American Medical
Association physician survey, physicians and their teams spent an average of almost 14.9 hours
each week completing prior authorizations (AMA, 2018). Any time spent processing these
medication PAs is considered a delay, and the literature demonstrates that these delays result in
worsening disease status due to missed medication doses, decreased overall medication
adherence, and increased medication abandonment.
Available Knowledge
Literature Review
A literature search using the PICOT methodology (Dang & Dearholt, 2018) was
conducted. It asked the following evidence-based, practice searchable question: “Will a post IT
project optimization with a user adoption and satisfaction evaluation reduce delays in receiving
medications requiring PA in a pediatric chronic disease population?”
The databases PubMed, OVID Medline, CINAHL, and Business Source Premier were
searched (2000 to present) using the following keywords: medication prior authorization,
electronic prior authorization, post implementation, evaluation, health IT, optimization,
medication delays, user adoption, informatics, project evaluation, and summative evaluations.

11
Over 160 articles were returned and after review of the titles and/or abstracts, 14 were found to
be relevant. They are detailed in the Literature Review Table (Appendix A). The articles were
reviewed for study design and quality as defined by the John’s Hopkins Research Evidence
Appraisal Tool and Non-Research Evidence Tool (Dang & Dearholt, 2018).
The articles consist of six level IIIs, three level IV, and five level Vs and can be applied
to several different specialty divisions at the pediatric organization. The first six explore the
impact of medication PA on clinical outcomes and support the background premise that
medications requiring PA result in poorer health outcomes for pediatric patients with chronic
diseases. The last eight articles fall under the category of intervention and support possible
interventions such as centralized PA teams and automated ePA systems.
Synthesis of the Evidence
Impact of Medication Authorization Delays
There were six articles supporting the evidence-based premise (EBP)—that medication PA
delays result in worsening clinical outcomes. All were high or good quality level III and were
published within the last decade. They were nonexperimental, quantitatively designed, and used
sample sizes greater than 100. The Bergeson article (2013) was most representative as it was
specific to the diabetic population defined in the problem statement and also had a large amount
of data culled from Medicare claims databases. Bergeson found that patients with approved PAs
maintained current therapy at higher rates than those with denied PAs.
The article by Shah (2014), a meta-analysis of fourteen other studies, was also strong. It
aggregated a large pool of data and found that even though medication PA restrictions may result
in cost-savings, they must be considered within the context of patient safety and quality of life
concerns. The strengths of a meta-analysis study are also the study’s limitations, as the Shah
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study pulled from such a large sample size that it may have inadvertently included patients who
should have been excluded from the dataset, such as inpatients and outpatient surgery patients.
Neurology/epilepsy was the 3rd highest specialty division requiring PA medications at the
pediatric organization. According to Wirrell (2018), patients with new onset epilepsy
medications requiring PA experienced delays in receiving them and consequently experienced
more seizure activity.
The other four articles, while not specific to the most common chronic diseases in the
pediatric population, were relevant as they related to other chronic disease conditions such as
dermatology, cardiology, and rheumatology and supported the same finding of worsening
clinical outcomes due to delays in receiving PA medications. All seven articles reviewed
medications critical to the primary treatment of their respective diseases. Taken together, all
provide a good foundation for the background of the EBP premise—that delays from medication
PAs result in worsening clinical outcomes in patients across several specialty divisions.
Evidence Supporting Possible Interventions
There were eight articles supportive of possible interventions. Three were consensus
statements from prominent healthcare organizations: the Office of the Inspector Generals (OIG),
the American Medical Association (AMA), and the Academy of Managed Care Pharmacy
(Academy of Managed Care Pharmacy Professional Practice Committee, 2019: American
Medical Association [AMA], 2019: U.S. Department of Health and Human Services-Office of
the Inspector General, 2019). Two of these three consensus statement articles provide references
and data in support of their recommended interventions, but it must be noted that many of these
references come from vendor specific data sources and are thus considered gray articles. Though
these three articles are of lower evidence level, they also are consistent in providing very specific
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actions and interventions designed to address the problem in the EBP question and contribute
heavily in the possible interventions for this QI project.
All three consensus articles suggest five interventions or action items, two of which are
specific to insurance companies. This QI project will focus only on those interventions specific
to health care organizations. The interventions suggested are as follows:
1. Insurance companies reduce medications requiring prior authorization by continually
reviewing data supporting efficacy and clinical impact.
2. Insurance companies improve communication with patients/families and providers
regarding medications requiring PA.
3. Health care organizations implement a centralized team to process medications requiring
PA.
4. Health care organizations implement an automated electronic prior authorization (ePA)
system.
5. Health care organizations standardize the electronic transactions between pharmacies and
insurance pharmacy benefits management systems and patients.
There was only one article of good quality specifically suggesting an automated
electronic medication PA solution to reducing delays and denials in medication PAs. This was
not surprising, as electronic medication PA systems capable of interfacing with an organization’s
EHR were not available until 2015 when CoverMyMeds© announced its integration with Epic
Systems©. The article by Bhattacharjee (2016) was a Level III non-experimental, qualitative,
ethnographic study in which the authors mapped the PA process for 29 community providers in
eight different organizations to determine problem points. The biggest limitation of this study
was that data capture occurred over a very short period of one week in April 2015. Again, the
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level IV and V consensus statement articles suggest automated electronic PA systems but the
references they provide are gray material sources coming from the only two electronic prior
authorization ePA API solution vendors currently available—Surescripts© and CoverMyMeds©.
According to a provider survey by CoverMyMeds©, 91% of respondents report that the PA
process results in delayed access to necessary care, and 75% report that the PA process leads to
patients abandoning treatment altogether (Resnick, 2020). The data provided by these two
vendors confirms the data reported in this article review: that there is a time delay for
medications requiring PA, and that an electronic medication ePA system integrated with the
EHR does reduce the time to authorization. Because they are not considered transparent and
unbiased, or rated as good or high quality, the references from these vendors are not formally
included in this synthesis of the evidence (Appendix A).
The Currie (2005) article, along with the Kaplan (2001) article, provide assessments of
different informatics evaluation frameworks and study designs which serve as foundations for
selecting the best summative evaluation tools for electronic medication prior authorization
system implementation, user adoption, and satisfaction.
Recommendations Based on the Findings
The pediatric organization implemented the ePA system in August of 2020. Based on
article findings, the intervention of a health IT project optimization with pre/post evaluation was
recommended. There were three articles supporting these possible interventions and many
articles supporting electronic health record (EHR) implementation evaluations, but none
specifically reviewing ePA system implementations. Most articles followed the methodology of
evaluating technical, clinical, usability, and cost outcomes from the IT project.
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Ward (2011) wrote a non-research level V, prospective post implementation survey of
high quality with a good sample size of over 705 nurses. The survey instrument used by Ward
(2011) was a validated tool and was implemented on nurses as the target participants. The article
provided clear transparency on survey methods, data collection, and the interpretations of the
data. While the article was limited in that it was not specific to ePA implementation, nor to the
pediatric or diabetic population, the article is relevant and can translate to possible interventions
such as centralized PA teams led by pharmacists to address the EBP question.
Kumar (2015) wrote a level V high quality article that was a prospective post
implementation survey. He completed a literature review of existing summative post
implementation survey tools and implemented a tool to evaluate EHR implementation within two
different organizations. This article is relevant to the EBP question as it reviews several
summative post implementation survey tools which can be used as interventions in this QI
project.
The third article from Cresswell (2012) supported post implementation evaluation and
optimization as a possible intervention. This was a high-quality Level III systemic review
comprised of meta-analysis of 13 articles. This study is particularly relevant for the intervention
of a post IT implementation optimization as the author assesses the technical, social, and
organizational factors impacting health IT projects. Several articles within the meta-analysis
assess the diffusion of innovation social science theory and its impact on user adoption and
satisfaction. Together, these three articles support the premise that increased user satisfaction and
adoption results in the increased use of health IT interventions such as electronic medication PA
systems.
Rationale
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Theoretical Model
Two theoretical models useful in guiding this project’s development are the Technology
Acceptance Model (TAM) and the Diffusion of Innovation Model (DoI). (Refer to Appendix B,
Figures 1 and 2).
The Technology Acceptance Model posits that user’s intent to use, and actual usage
behavior of a technology are predicated by their perceptions of the technology’s usefulness
(Davis et al., 1989). The TAM also suggests that perceptions of usefulness and usability are
influenced by external variables (individual differences system characteristics), as well as social
influences (organization culture and hierarchies, environmental conditions). This theory ties
directly to the relationship between user satisfaction, project optimization, and utilization of this
new ePA system.
The second model helping to guide this project is the Diffusion of Innovation theoretical
(DoI) model. This model is a social science theory explaining the adoption of innovation within a
population or social system such as healthcare workers (Rogers, 2003). The study of how
populations adopt innovations such as healthcare technology is important when evaluating new
technology implementations. User adoption of the electronic medication prior authorization
application will be important in evaluating its efficacy and relationship to desired outcomes.
Project Framework and Organization
To implement this QI Project, the Kellogg Logic Model (Appendix C) was used in
conjunction with the Gantt Chart Timeline (Appendix D) and the SWOT (Strengths,
Weaknesses, Opportunities, Threats) Analysis Table (Appendix E) to provide an overall
framework, establish baselines, evaluate potential obstacles, and implement pre- and postoptimization interventions.
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The Kellogg Logic Model provided the overall project framework for this project
(Kellogg, 2006). This logic model is crucial to project planning and evaluation, and offers a
clear, concise framework by aligning resources, activities, and outputs to specific outcomes. The
inputs in this model include the nurses, chronic disease pediatric patients, providers, ambulatory
operations leadership, and information technology leadership. The proposed logic model
outcomes are twofold: faster medication prior authorization time and increased user satisfaction
and adoption of the ePA system.
Specific Aims
The interventions being applied in this QI project aim to reduce the amount of time it
takes for PA medications to be approved, thus enabling patients to receive their medications
sooner, improving clinical quality outcomes for pediatric patients with chronic disease This
intervention will be accomplished by increasing the utilization of the ePA system and
streamlining workflow processes. A survey measuring user satisfaction and adoption will be
completed pre- and post-optimization. This QI project analyzes the relationship between the
optimization of the ePA system and user satisfaction and utilization (user adoption) and
evaluates whether improving user satisfaction results in increased utilization, thereby reducing
median medication PA approval times.
Context
Population
The populations being examined are twofold. The primary population is the ambulatory
nurses who perform the majority of the medication prior authorizations. There are roughly 200
ambulatory clinic nurses staffing 36 specialty divisions at the pediatric organization. Of these,
98% hold a bachelor’s degree in nursing or higher, and over 50% have greater than 10 years of
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experience. There are a few providers (physicians and advanced practice professionals) who also
perform prior authorizations, but they have been excluded from this QI project due to the
difficulty of separating them from the other ePA users.
The second population group is made up of chronic disease patients and families affected
by delays in receiving their PA medications.
It was difficult to measure chronic disease patient volumes at the pediatric organization.
A report based on chronic disease diagnosis’ who had a visit at the pediatric organization in the
last 2 years, which can be found in Table 3, page 44, estimates that there are about 54,00 active
patients. The endocrine division had roughly 800 inpatient admissions and 16,000 outpatient
visits in 2019. The pediatric organization has 368 licensed inpatient beds and 14 outpatient
centers. The organization has over 1,665 medical staff in more than 70 pediatric specialties and
provided care for over 212,860 unique patients in 2018.
Settings and Resources
The pediatric organizations diabetes program is certified by the American Diabetes
Association and provides care at another pediatric hospital in the south side neighborhood of
Chicago. The entire diabetes program includes six physicians, two advanced practice providers, a
medical director, one nurse manager, seven certified diabetes nurse educators (CDE), one
clinical diabetes nutritionist educator, and one psychologist. The nursing team is supplemented
with six more Endocrine division nurses who cross-cover the diabetes team as needed and
perform many medication PAs for endocrine patients. This is a multi-disciplinary, team-based
staffing model where each role (provider, educator, nurse, nutritionist, psychologist) is
responsible for specific parts of care for our diabetes patients. The diabetes team also has a
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robust research program and leads, or is involved in, multiple high value grants and
collaboratives.
The team treats patients at six outpatient centers, with the primary diabetes center located
within the outpatient center in the Lincoln Park neighborhood of Chicago. The primary diabetes
center has 6 exam rooms, a lab, an education room, a team room with seven workstations, a
nurses’ station, and an outpatient psychologists’ room. The diabetes nurse’s office, where most
medication PAs are completed, is in an office building across from the hospital. Each nurse has a
cubicle with a phone and computer. All providers and some nurses are granted access to the
hospital’s secure Virtual Private Network (VPN) which grants remote access to the Epic EHR
and secure telephony and allows them to perform medication PAs remotely.
The pediatric organization provides the resources of a change management system
supportive of project requests such as this and manages all projects through an Enterprise Project
Management Office (EPMO). This office determines the resources needed for project support
and brings the projects to senior leadership for decisions to scope and implement. It is the EPMO
that verifies support from the various teams such as Information Technology, Process
Improvement, Facilities, Pharmacy, Risk/Legal, and aligns the resources to reduce and resolve
conflicts.
Project Alignment with Organizational Mission, Values, Strategies, and Needs Assessment
The pediatric organization is a free standing, not for profit, pediatric tertiary care hospital
located in the urban setting of Chicago, Illinois. It is a mission-based organization committed to
the health and wellness of all children. This vision is guided by the belief that all children need to
grow up in a nurturing and protective environment in order to reach their fullest potential. In
2017, the pediatric organization implemented a strategic plan called Vision 2025 and set the goal
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of achieving top tier pediatric organization status by 2025. This QI project aligns with another
pillar of Vision 2025, which is to provide the best patient care and experience possible.
The needs of the organization are continually being evaluated and projects are prioritized
to ensure alignment with the mission and vision of the organization. The problem of delays in
medication PAs and the potential interventions has been reviewed with senior ambulatory
nursing leadership and the ambulatory leadership team. These senior nursing leaders assisted in
identifying potential interventions and agree that there is a need for further improvement.
Evaluating Change and Readiness for Change
The pediatric organization has the organizational capability and appropriate resources to
support multiple interventions and is ready for change. It has committed resources to address the
interventions suggested and has formed a centralized nursing team to complete PAs. This
centralized team has already demonstrated improvement in reducing PA denials as well as PA
medication turnaround time.
In addition to providing the necessary resources to address the suggested interventions,
the pediatric organization also implemented an ePA system capable of integrating directly with
the EHR and workflows. Strong internal data supported both interventions and the pediatric
organization provided defined resources and support for the project and its interventions. The
two projects were reviewed, scoped, and approved through the pediatric organizations EPMO
team to ensure alignment with organizational mission and vision, and that resources such as
information management, operations, and data analytics were scheduled during the planned
implementation timeline.
Key leaders in the diabetes, allergy/pulmonary, and neurology/epilepsy centers agreed to
the proposed interventions to optimize and evaluate user satisfaction with the recently
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implemented ePA system. Team members were engaged to develop the measures and
interventions required to address the problem of PA medication delays and denials in the
specified pediatric chronic disease population.
The ePA implementation team consisted of our Chief Medical Information Officer, the
Clinical Practice Directors for Endocrinology, Allergy, and Pulmonary, five front line chronic
disease nurses, the nurse manager and director, information management EHR analysts, EHR
training team, a clinical pharmacist who currently leads our centralized prior authorization team,
the Senior Director for Digital Health, and the Director for Nursing Informatics and Innovation
as well as the Ambulatory operations leadership team. This team will remain in place after
implementation and will provide continued support for this QI project. Senior leadership (Chief
Nursing Officer and Vice President of Ambulatory Services) are the sponsors for the ePA project
and understood their roles in addressing barriers and in served as final decision makers.
Strengths and Weaknesses
The project steering team agreed that the strengths of the optimization intervention of the
ePA system lie in reducing delays and denials receiving medications, which in turn is expected to
improve clinical outcomes. Additionally, the investment could provide a cost savings to the
organization in the form of reduced readmission rates, reduced emergency visits, reduced
medication denial rates, and increased user adoption and satisfaction along with the more
efficient use of organizational resources who process these PAs.
Alignment with the organization’s mission and vision is important to receiving the
resources and support for a successful project outcome. Another strength aligning with the
organization’s mission is that chronic diseases such as diabetes are strategic targets of the
organization’s recent community health needs assessment. This assessment identified and
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targeted underserved and under resourced communities on the west and south sides of Chicago
and implemented local plans designed to improve patient access in an ongoing effort to prevent
and treat diabetes.
One weakness within the pediatric organization was that the diabetes team is already
stretched thin with involvement in multiple research and organizational projects. Additionally,
the endocrine division was transitioning to new physician leadership, which could potentially
change the direction and priorities of existing projects. There was the possibility that
interventions to address delays and denials in medication PAs could be de-prioritized in favor of
other competing projects. Additional threats included competing organizational resources such as
information technology.
Memorandum of Understanding (MOU)
The memorandum of understanding (MOU) (Appendix F) is the agreement between the
DNP student and the organization. It outlines the terms and understanding between the student at
Boise State University and the pediatric organization. The reviewed, approved, and signed MOU
for this QI project was signed by the principal investigator and the pediatric organizations chief
nursing officer on December 22, 2020.
Interventions
Logic Model
The logic model by W.K. Kellogg Foundation (2006) provided the framework for
evaluating and planning this QI project. As stated earlier, the focus of the logic model is to align
resources, activities, and outputs to specific project outcomes. Outcome goals were developed
using the SMART (specific, measurable, achievable, realistic, and timely) acronym. The key
outputs for this project are:
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1. An initial summative evaluation of the ePA system and corresponding report to
stakeholders,
2. An informatics user adoption and satisfaction survey,
3. An optimization plan and implementation, and
4. A post optimization evaluation and user survey.
To achieve these outputs, several activities were accomplished.
1. A multidisciplinary steering team was organized with an initial meeting in April
2021.
2. Summative evaluation report of the ePA system was scheduled and reported to
stakeholders in April 2021.
3. The plan to revise the algorithm for automatically verifying pharmacy benefits,
reducing nuisance medications that require PA, and streamlining the workflow for
the top 10 most frequently ordered PA medications was implemented in early
June 2021.
4. An informatics user survey was selected and administered the first week of June
2021 and again after optimization in August 2021.
These project resources (team members) include ambulatory nurses in chronic disease
specialties, providers, pharmacists, ambulatory operations leadership, clinical informaticists,
EHR educators, and information technology (IT) specialists. A core team of leaders was
organized, including ambulatory operations leadership made up of the nursing director and 3
managers, the IT EHR Manager, the pharmacy lead for the centralized authorization team, the
physician clinical practice director for our diabetes program, an advanced practice professional
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from another chronic disease specialty, the chief medical information officer, and the director of
nursing clinical informatics.
The short- and long-term goals in the logic model format are listed in the table below:
Table 1. Short and Long-term Outcome Goals
#1
#2
#3
#4
#5
#6
#7
#8
#9
#10

#18
#19
#20
#21
#22

SHORT-TERM OUTCOME GOALS
Initial evidence-based post IT project summative evaluation (clinical, operations, financial) reported to
stakeholders by June 7th, 2021.
Initial evidence based validated user survey administered to 75% of identified user community by June 7 th,
2021
58% of medications requiring PA receive approval on first PA submission by August 31st, 2021
75% of medications requiring prior authorization are approved within 48 hours of order submission by
August 31st, 2021.
5% reduction in time taken from medication order to medication PA approval from baseline data by
August 31st, 2021.
75% of visits will have pharmacy benefits verified by August 31 st, 2021.
75% of users complete optimization education.
Electronic medication AP system user adoption rate greater than 75% post optimization.
Electronic medication PA system user satisfaction rate greater than 50% post optimization.
Greater than 50% response rate to an electronic medication PA post implementation evaluation user survey
post optimization.
LONG-TERM OUTCOME GOALS
Evidence based informatics project evaluation completed pre and post every electronic health records
(EHR) project.
Evidence based validated user surveys completed pre and post every EHR project.
Improved disease status and chronic disease control, i.e. Glycemic control for diabetes patients, decreased
seizures for epileptic patients.
New users continue to utilize the electronic medication PA system at a rate higher than 80%.
Consistent evaluation of user adoption and satisfaction after every EHR project.

Correlation of Interventions with Theoretical Model Elements and Phases
The Technology Acceptance Model (TAM) correlates IT system usage with its perceived
usefulness. If users’ perceptions of the usability and overall usefulness of the new ePA system
are improved, increased usage of the ePA system should result, which in turn should reduce PA
processing times. The Diffusion of Innovation (DoI) Model provides social behavior guidance on
how informatics users will adopt new technology and suggests ways to enhance user acceptance.
The initial intervention of a summative evaluation exploring PA processing times along with
user adoption and user satisfaction provides baseline measurements of the effectiveness of the
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ePA system. These two theoretical models may be related, as DoI early adopters may have a
more positive perception of the usefulness of an innovation and therefore be more likely to use
the ePA system. Conversely, users with less positive perceptions of an innovation’s usefulness
may be more likely to discount the system, using it less often. Implementing an optimization
based on these initial evaluations may increase user adoption and satisfaction, resulting in
reduced PA approval times and improved clinical outcomes for our chronic disease patients.
Timeline
A Gantt chart timeline is found in Appendix D. The key milestones are:
1. Planning: (October 2020–May 2021)—Organize core team, determine key performance
measures, develop user satisfaction survey, develop detailed optimization plan.
2. Implementation: (June 2021–Aug 2021)—Optimization and pre/post survey.
3. Data Collection: (June 2021–Aug 2021)—Collection of key performance data and survey
results.
4. Data Analysis: (June 2021–August 2021)—Analysis of key performance data and survey
results.
5. Dissemination: (Fall of 2021) —Communication of final report and decision to publish.
Measures
The two most important data measures for the DNP SP are 1. the amount of time required
for a medication requiring prior authorization from order to authorization approval (ePA
turnaround time). 2. The nurses’ user satisfaction with the ePA system. The source for the
medication PA approval times will be the organization’s EHR—Epic, from existing PA approval
time reports. This data element will be measured pre- and post-intervention of electronic prior
authorization system optimization. Verification of pharmacy benefits is key to enabling and
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enhancing the effective use of the ePA system. Currently, this is being performed on 71% of
visits at the pediatric organization. The optimization intervention will include revising the
algorithm to automatically verify pharmacy insurance benefits. Therefore, pharmacy benefits
verification will also be measured using existing EHR reports.
For the second data measure, user satisfaction will be collected using a survey
questionnaire with a 5-point Likert scale question rating overall user satisfaction and providing
interval-level data (Illowsky & Dean, 2018). This statistic will also be measured pre- and postoptimization intervention. There are many validated user satisfaction questionnaires, but none
are specific to medication prior authorization APIs. The validated Doll and Torkzadeh User
Involvement survey was adapted to be more specific to evaluating electronic medication prior
authorization systems (Doll & Xia, 1997). This user involvement survey is further categorized as
follows: content, accuracy, format, timeliness, ease of use, and overall satisfaction. The user
Involvement survey questions, along with the user data points being collected in this QI project,
are found in Appendix G. An additional data measure from this survey questionnaire is a single
qualitative open-ended question within a free text comment field (Appendix H). A complete
Outcomes Evaluation Table can be found in Appendix I.
Analysis
Quantitative Analysis
Both descriptive and inferential statistical analysis were used as data measures for this QI
project. Descriptive statistics was used to analyze the electronic prior authorization process and
user satisfaction. The first data point compared the central tendency measure of median ePA
approval times before and after the intervention of an optimization to the electronic prior
authorization process. The median ePA turnaround time data was used rather than the average, in
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alignment with benchmark reports set by other organizations. The second data point evaluated
the percentage approval rate of ePA submission while a third data point analyzed the percentage
of visits with pre-verification of pharmacy benefits. Data collected using these sources and
collection methods, along with descriptive statistical analysis, determined the effectiveness of the
optimization intervention.
Qualitative Analysis
For this QI project, qualitative user experience data was collected using an open-ended
question. The data collected was grouped by user satisfaction and user adoption, with
subcategories of perceptions of specific portions of the ePA process and EHR functionality. The
qualitative survey data was grouped based on topics to identify opportunities for correcting the
process and improving final outcomes.
Accuracy, feasibility, utility, propriety, and accountability standards were applied when
collecting and analyzing qualitative data (Newcomer et al., 2015). To remove the project
manager from any potential reviewer bias concerns, the survey itself was administered by a nurse
on the pediatric organizations Clinical Informatics team. The project team was trained on the
processes required to maintain privacy, confidentiality, and transparency, along with maintaining
quality (accuracy) of data collection. This QI project was reviewed by the sponsoring
organization’s Institutional Review Board and the project team was held accountable for
maintaining evaluation standards.
Ethical Considerations
Protection of Participants
Ethical considerations to protect project participants’ privacy and confidentiality are
paramount to this project. The project participants are the users of the electronic medication PA
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system. This author completed Collaborative Institutional Training Initiative (CITI) on human
subject research in July 2020. Based on the CITI training, the core principles of informed
consent, voluntary participation, confidentiality, privacy, do no harm, and assessing only relevant
components of information will be complied with during all phases of this project. One ethical
risk is coercion, as this author supervises the nursing staff who use the electronic PA system.
Consequently, nursing staff may feel obligated or compelled to use the system or be biased in
survey feedback and response. However, according to CITI training, this project is considered
low risk as it is primarily considered a quality improvement project—one using de-identified
data and not requiring informed consent.
Further, the author avoided using identifiable data and used only the minimum amount of
relevant data required to complete the project. Patients’ medication PA time data was retrieved
as de-identified data from the secure EHR in compliance with the pediatric organizations
institutional data resource policy and in compliance with the Health Insurance Portability and
Accountability Act (HIPAA). User survey data was de-identified as much as possible to further
ensure privacy and confidentiality.
Conflicts of Interest
This author has no conflicts of interest to disclose. There are no financial considerations
or other benefits from any of the initiatives selected. The author maintains no conflicts related to
electronic PA system product utilization, pharmacy benefits insurances, validated survey vendor,
or pharmacies.
Biases
There are several potential biases for this project, among them the inherent biases and
social aspects of adopting and accepting new technology. Per the Diffusion of Innovation theory,
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some users may be early adopters, encouraging others to use the new ePA system, while others
may be laggards who never adopt the innovation. There may also be a social desirability bias,
where user survey respondents may be biased to answer questions in ways they perceive will be
viewed favorably by others in their social community. There may be a bias toward the prior
system of faxes, phone calls, and online portals for processing PA medications as well. These
biases may impact survey participation rates, honesty of responses, and hamper optimization
improvement efforts.
Threats to Quality
Quality threats identified for this project include missing or incomplete data, concerns
with reliability and validity of the data measured, and low survey participation rates. The primary
data source for medication prior authorization processing times will be the pediatric
organizations EHR and its integration with the electronic PA application program interface. This
is a possible threat to reliability as unplanned service interruptions in either system could result
in corrupt or incomplete data. The two user surveys and optimization education could also be
negatively impacted by low participation rates. The survey tool selected and the method by
which the survey is conducted will need be validated to ensure that appropriate information is
being captured without bias.
IRB Application and Project Determination
This QI project was presented to the pediatric organization’s Institutional Review Board
(IRB) for determination on January 26, 2021, and a Letter of Determination indicating that this
project met criteria for Quality Improvement (QI) was issued on February 11, 2021. Per the
pediatric organizations existing policy, this QI project does not meet the definition of human
subject research and does not require IRB review or informed consent for participation.
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Project Budget
The resources required to support and sustain this QI project over a 3-year budget period
are detailed in three documents: a 2–3-year projected Budget (Appendix J), Expense report
(Appendix K), and a Statement of Operations (Appendix L). Key elements of this QI project are
the implementation of a user satisfaction survey pre- and post-intervention and three
interventions: two information technology (IT) interventions and one operational optimization of
the ePA system. The expense report details the labor expenses required to support these
interventions. The primary labor components are the project steering team, the IT analysts who
support ePA system integration within the electronic health record (EHR), data and reporting
resources, and EHR educators. All budget resources are considered organizational and are to be
provided in-kind from the pediatric organization.
Sustainability
To sustain this QI project financially into the second and third year and to continue to
evaluate the outcomes and recommend possible further interventions, project management labor
and minimal project steering team labor are required. There are also yearly IT interface fees
currently being evaluated to determine whether they fall under this QI project budget. The threeyear projected cost is $24,535.50. This QI project was not designed to generate revenue and
since the primary source of revenue will be in-kind donation, the resulting operating income will
be $0 as detailed in the Statement of Operations.
Continuous quality improvement should be sustained within the QI project through
yearly reviews and technical and operational optimizations to the ePA system. These reviews and
optimizations should occur in conjunction with the centralized prior authorization team, as this
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will provide the most thorough assessment of the systems in place to address patient delays in
receiving PA medications.
Results
Steps of the Interventions
The quality improvement kick-off meeting was held on April 30, 2021, with the steering
team representing ambulatory nursing operations, clinical informatics, information management,
information technology (interface lead), pharmacy informatics, clinical physicians, the
centralized prior authorization team, and frontline ambulatory nurses. The organization’s ePA
summative reports on turnaround times, approval rates, and pharmacy benefit insurance with
patient validation rates were presented as baseline data. User involvement survey questions and
demographics questions were proposed and approved with only one change (adding the question
of “how many years of experience do you have completing medication prior authorizations”).
Three optimization interventions were proposed and approved:
1. Reduce medications falsely requiring PA
2. Increase the patient-pharmacy benefits auto validation rate
3. Optimize the workflow for attaching documents within the ePA.
An informatics nurse emailed the pre-intervention user involvement survey to 100%
(n=194) of the ambulatory nurses on May 5, 2021 and sent a follow-up reminder on May 24,
2021. The pre-intervention survey period ended on June 1, 2021. There were three meetings with
staff from the following specialties: endocrine (diabetes educator), psychiatry, and the
centralized prior authorization team. At the meetings, participants provided feedback on
improving the ePA workflow along with specific interventions to improve the process of
attaching documents to ePA communication.
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The nursing informatics consultant sent the post optimization user involvement survey on
August 3, and a reminder email was sent on August 23. Due to a very low response rate, the
Chief Nursing Officer sent a third email reminder on August 27, 2021, and extended the deadline
to September 7.
Interventions
The optimization included three interventions to the ePA system.
1. Reduce medications falsely requiring PA by removing them from being processed
in the CoverMyMeds application program interface (API).
2. Increase the pharmacy insurance verification rates by modifying patient matching
validation criteria.
3. Modify the process of attaching data from the EHR into the ePA communication,
improving workflow efficiency.
A report identified 38 medications often flagged erroneously as requiring PA, most of
them over the counter (OTC) medications. Most OTC medications require medication PA
because patients can obtain them over the counter and pay out of pocket (not paid for by
pharmacy benefits). The specific intervention excluded the 38 medications from requiring ePA in
the Epic EHR. See Appendix M for the specific list of medications excluded from ePA.
For the ePA system to work, the first step must be to verify the patients’ pharmacy
benefits. The EHR and pharmacy benefits vendor are electronically interfaced and attempt to
automatically match patients with their respective pharmacy benefits insurance through a
validation algorithm. This validation is automatically completed every morning prior to the
scheduled patient visit appointments. The interface report revealed that over the period of March
to early June 2021, an average of 40 interface errors occurred per day in attempting to match
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patients to their pharmacy benefits. The matching rate prior to the interventions was
approximately 70% of scheduled patient visits. The interventions modified the patient matching
validation logic by removing the “gender” criteria from the EHR interface with the goal of
increasing this automatic matching rate 5% by August 2021. Refer to Appendix N for
screenshots of the Interface Validation Changes completed in the Epic interface.
The third optimization intervention was to improve operational workflow efficiency
within the ePA system. Small group meetings with frontline nurses revealed a multi-step
workflow for attaching documents to the ePA system:
1. Copy all specific parts of the patient’s EHR record.
2. Paste into a Microsoft Word document
3. Modify Word document as needed by removing/adding sections
4. Print the Word document
5. Scan the printed document
6. Retrieve the scanned document from email and save/rename to a secure drive.
7. Attach the document to the ePA communication.
Working with frontline staff, the team developed a new workflow with fewer steps, thus
reducing the amount of time it took to attach documents to ePA communications. Ambulatory
nurses were instructed on best practices for attaching the documents and were educated on the
new workflow and This intervention was implemented on June 21st, 20221. Please refer to
Appendix O—Attaching Documentation to ePA Communication.
Study of Interventions
Pre-Optimization Study of Interventions
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The 13-question user involvement survey was completed on June 1st, 2021, prior to the
implementation of the optimization interventions and provided baseline user satisfaction and
adoption information.
There were 57 responses with the following demographic breakdown. Survey
respondents averaged 16 years of experience with a range of 2–46 years. Their average years of
experience completing PAs were 5.7 years with a range of 0–25 years. Respondents reported
completing PAs two times a week on average with a range of 0–10 times a week. By specialty
primary care pediatrics logged the highest response rate at seven total.
A twelve-question user involvement survey using a five-point Likert scale was completed
by 51 respondents. The pre- and post-optimization involvement survey results are graphed in the
figure found in Appendix Q. Most respondents (51%) reported that the system was not user
friendly and 49% reported dissatisfaction with system accuracy. The two questions with the
highest satisfaction rates were “does the system provide the information you need?” and “is the
information clear?” with respective satisfied scores of 46% and 39%.
The ePA initiated volumes have steadily increased from December 2020–March 2021
with the highest mark in March at 1,136 PAs while the ePA median turnaround times have
remained steady at around 36 hours over the same period. The overall approval rate averaged
54% from October 2020–March 2021.
Post Optimization Study of Interventions
The 13-question post optimization user involvement survey was completed on September
7th, 2021. There were 16 responses with demographics as follows. Survey respondents had an
average 18.8 years of experience years with a range of 4–40 years. They averaged 6.6 years of
experience completing PAs with a range of 0–20 years. Respondents reported completing PAs
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seven times per week on average with a range of 0–60 times per week. By specialty,
pulmonary/sleep medicine respondents had the highest response rate at three total. For a
summary of this information, refer to appendices P and R.
A twelve-question user involvement survey using a five-point Likert scale was completed
by 16 respondents. The post optimization involvement survey results are graphed in the figure
found in Appendix N. Most respondents (53%) reported that the system was not user friendly
and 51% reported that they were dissatisfied with its accuracy. The two questions with the
highest satisfaction rating were “does the system provide the information you need?” and “is the
information clear?” with respective scores of 40% and 36% satisfied.
The ePA initiated volumes slightly increased during the optimization intervention period
of June–August 2021 with the highest mark in June of 1,313 PAs while the ePA median
turnaround times remained stagnant at around 36 hours over the same period. The overall
approval rate dropped from 55% to 47% at the end of the August 2021 optimization period.
Contextual Elements Interacting with the Interventions
The implementation of the ePA system in August 2020, coincided with the global
COVID-19 pandemic, during which time inpatient and emergency department patient visit
volumes dropped by roughly 50% while outpatient visit volumes declined by roughly 10%.
Many in-person outpatient visits were replaced with telemedicine appointments, which peaked at
roughly 70% of outpatient visits during the month of April 2021. This drop in inpatient
admissions led to significant financial strain on the pediatric organization, resulting in
implementation of a financial recovery plan that saw a 10% workforce reduction and unpaid 6week furloughs for all organization employees. Despite less impact on outpatient visit volumes,
the furloughs and reduction in workforce increased the strain on ambulatory nurses, who were
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often short staffed. Initial ePA implementation was delayed by 4 weeks due to the strain on
Information Management (IM) project resources and ambulatory nurses.
The interventions of this project were implemented during the months of May through
August 2021, just as outpatient visit volumes returned to pre-pandemic levels. As vaccination
rates increased and Chicago relaxed COVID precautions, a surge of patients returned for inperson healthcare and some divisions experienced 17% higher visit volumes without a
corresponding increase in staffing. The steady increase in ePA volume during the winter of 2020
going into 2021 continues to strain ambulatory nursing resources, resulting in lower employee
engagement scores and possibly resulting in stagnant ePA turnaround times pre optimization
intervention.
An unplanned EHR upgrade was performed mid-July and impacted the operational
intervention for improving the workflow for document attachment. The upgrade turned the EHR
PA Details webpage containing document attachment instructions into a dynamic weblink,
resulting in confusion over correct processes and workflow best practice’s location. The training
document was not corrected until the end of August, which may have reduced utilization of the
ePA API system.
Discussion
Summary
The final report on desired outcomes post interventions shows that the majority of the
outcome goals were not met. The primary outcome goal of reducing turnaround time for
medications requiring prior authorization remained at 36 hours, while the approval rate at the end
of the observation period in August 2021 dropped from 55% to 47%. Each optimization
intervention was intended to increase overall use of the ePA system, thereby reducing the
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amount of time taken for patients to receive their PA medications. The following table outlines
the interventions along with desired short-term outcomes and results. While interventions to
increase the availability of the ePA system by increasing the auto verification rate of pharmacy
benefits were successful at 75%, there was only a slight increase in overall PA submissions from
June–August 2021. See Appendices S and T—ePA Volumes and Turnaround Times Report Pre
and Post Optimization.
An overall summary table of interventions and short-term related outcomes is depicted in
Table 2 below. Table 3 illustrates the optimization ePA metrics, with the intervention and
implementation period highlighted.
Table 2:
Summary Table of Interventions and Short-Term Related Outcomes

1

2

3
4

5

6
7
8

9

Goal #
Initial evidence based post IT project
summative evaluation (clinical,
operations, financial) reported to
stakeholders by June 7th, 2021
Initial evidence-based validated user
survey administered to 75% of
identified user community by June 7th,
2021.
58% of medications requiring PA are
approved by August 31st, 2021.
75% of medications requiring PA are
approved within 48 hours of order
submission by August 31st, 2021.
5% reduction in time taken from
medication order to medication PA
approval from baseline data by August
31st, 2021.
75% of visits will have pharmacy
benefits verified by August 31st, 2021
75% of users complete optimization
education
Electronic medication PA system user
adoption rate greater than 75% post
optimization
Electronic medication PA system user
satisfaction rate greater than 50% post
optimization

Intervention
Summative evaluation—Kickoff
meeting

Pre-Optimization Survey

3 Optimization Interventions

Met/Unmet Date
Met
April 30th, 2021
Met
100% (194/194)
received the email.
Return rate 57/194
Not Met
46% August 2021

3 Optimization Interventions

Not Met
65% August 2021

3 Optimization Interventions

Not Met
36 hours—August 2021

Pharmacy benefits validation
optimization
Attaching documents
optimization

Met
75.2% September 2021
Not Met
45%

3 Optimization Interventions

Not Met

3 Optimization Interventions

Not Met
–80% August
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Greater than 50% response rate to an
electronic medication PA post
implementation evaluation user survey
post optimization

10

Not Met
8% (16/194) post
intervention response
rate.

Post optimization survey

Table 3:
Optimization ePA Metrics. Intervention period highlighted in dark.
January

February

March

April

May

June

July

August

Measure

2021

2021

2021

2021

2021

2021

2021

2021

PA’s Initiated

890

1,093

1,136

1,133

1,143

1,313

1,130

1,251

24,748

25,434

29,521

28,111

27,225

29,777

27,121

28,447

3.6%

4.3%

3.8%

4%

4.2%

4.4%

4.2%

4.4%

35

36

36

38

37

36

38

36

54.8%

54.2%

52.7%

55.27%

55%

55.7%

46%

46.9%

NA

NA

NA

70%

71%

74%

76%

75%

Ambulatory Visit Volume
(excludes medical imaging,
diagnostics testing and rehab)
ePA/Visit Ratio
Median Turnaround Time
ePA Approval Rate
% of ambulatory visits with
pharmacy benefits auto
verified

Comparison of pre- and post-intervention user satisfaction surveys revealed a drop in the
survey participation rate from 29% to 8%, with a significant drop in overall user satisfaction
measured as the Net Promotor Score (NPS) fell from –70 to –82. The lowest ratings continued to
be regarding the accuracy and timeliness of the system in both pre and post surveys. The openended free text question also relayed the same issues with accuracy and timeliness of the ePA
API.
The overall project expenses came in under budget as additional EHR interface engineer
time was not needed to implement the new inbound/outbound interfaces. There is also no
expense for data and reporting analyst time as pre-existing reports from CoverMyMeds and the
EHR met the needs of this quality project. A summative report was sent out to the project team
and stakeholders in December 2021.
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Interpretation
Association between Interventions and Outcomes
The intervention of increasing the pharmacy benefits auto validation rate was intended to
be a leading indicator for reducing the medication PA turnaround time. It was felt that increasing
the availability of the ePA API in clinic visits would allow the ePA system to be utilized more
often, therefore decreasing medication turnaround times. Though the intervention to increase the
pharmacy benefits validation rate was achieved at 75% of ambulatory visits, this did not appear
to translate to increased utilization of the ePA system because the ratio of PA to visits remained
constant around 4% during the June–August observation period.
The intervention to reduce the number of medications falsely requiring prior
authorization had mixed results. This intervention was designed to reduce the administrative
burden of completing PAs for medications not requiring authorization. This intervention may
instead have resulted in an unintended reduction of the authorization approval rate. Further
examination of the decreasing approval rate found that many of the medications removed from
requiring PA were approved at a high percentage rate in prior months. Removing these
medications from the denominator of approved ePAs possibly resulted in an overall lower
approval percentage.
The operational improvement intervention of attaching documents contributed to an
increase in approved authorizations in the first month’s post intervention but had to be changed
in mid-July due to an EHR upgrade which moved the prior authorization details page into a
separate screen without documentation or explanation, causing confusion among users. A new
workflow needs to be developed to incorporate this change in EHR.
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The user satisfaction post intervention results demonstrate dissatisfaction with the ePA
API system. Based on the feedback broken out into different informatics subjects (accuracy,
usability, timeliness, format), the ambulatory nurses are highly dissatisfied with the ePA system.
The use of an alternative electronic medication prior authorization system was not
included in the quality improvement project. The ePA API vendor, CoverMyMeds (CMM) also
offers an online portal for completing prior authorizations. This online portal is an approved
system for the organization’s nurses to use and the pediatric organization does maintain a
separate contract with CMM for its use. During the intervention and monitoring period,
utilization of the ePA API system was compared to the CMM online portal, and the PAs created
by month in the online portal averaged 862 from June–August 2021, which is a little less per
month than the ePA API, but the authorization rates for the CMM online system are significantly
higher at an average of 73% during the same time period. Based on responses to the open-ended
question at the end of the survey, nurse users found the online portal to be more accurate,
timelier, and easier to use than the integrated ePA system. There were negative comments
regarding the inability of multiple users to track an ePA in the integrated system, along with it
being more difficult to revise an ePA versus having to completely cancel an ePA in comparisons
of the two PA systems. Again, this quality improvement project did not intend to compare the
integrated ePA system with the online CMM portal PA system but, considering the impact of this
alternative medication PA system, comparisons should be included in future project work.
Limitations
The quality of the post optimization survey results may have a negative response bias due
to the low percentage response rate (8%). The low rate may only represent the most negative
survey responses and there may also be an element of non-response bias. As stated earlier,
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ambulatory nurses are currently stretched thin due to high patient volumes and acuity, which
may have contributed to their non-responses to this follow up post optimization survey. The
survey end date was extended by 10 days from August 27th to September 7th, 2021, to help
accommodate for this response rate concern.
Another possible limitation is the ability to replicate and generalize this QI project. While
the general process of evaluating an existing healthcare informatics system, obtaining user
satisfaction information to inform interventions, then measuring for success can be applied to
other informatics projects, the technical specifics that vary between informatics projects may be
difficult to scale. At a strategic decision-making level, the opportunity costs may not allow for
this general process to be resourced.
Policy Implications
There are several levels of policy that govern the use of the ePA system and are
considered with this QI project. At an organizational level, health information management
policy defines the rules and regulations for using and maintaining the electronic health record to
assure the health, safety, and security of the data and the staff who use it. These policies are also
aimed at protecting the organization from legal risk. Many of these rules and regulations are
designed and programmed into information systems to comply with policies, while others are
managed through operations. With this QI project, patient identification and pharmacy benefits
interface settings were changed in compliance with IT policy.
At a national and international level, policies promoting interoperability and standard
electronic communication while complying with government policy such as the Health
Information Portability and Accountability Act (HIPAA) and the Medicare Prescription Drug,
Improvement, and Modernization Act are required. The integrated ePA system that was
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optimized with this QI project is in full compliance with the National Council for Prescription
Drug Programs SCRIPT Electronic Prior Authorization Transaction Standards established in
2015 (NCPDP, 2015). The NCPDP is a not for profit, quality accredited, standards development
organization with members representing all aspects of the pharmacy industry—pharmacies,
payors, and healthcare organizations. The NCPDP SCRIPT ePA sets standard electronic
definitions and transactions for patient identification, prescribing, dispensing, insurance
verification, and payment and is approved by the U.S. Department of Health and Human
Services.
A clinical level of policies defining clinical operational workflows was also taken into
account. Nursing policies such as the medication refill protocol allow registered nurses to refill
most medications electronically. These nursing protocols are reviewed and approved by the
pediatric organizations Medical Executive Board and are organizational level policies.
Documentation standards are in place requiring attaching clinical documentation to the ePA
request and impacting the operational optimization for attaching documents to ePAs.
Conclusion
Though most of the outcome goals were not met with this QI project, these results, and
the unintended comparison of the two medication PA systems, demonstrate that informatics
users will naturally gravitate toward the system they perceive to better meet their needs. This
behavior aligns with the Technology Acceptance Model theory and may be valuable in
predicting user satisfaction and user adoption of clinical informatics tools. Understanding user
behavior with informatics software is valuable when implementing healthcare QI projects.
One of the strengths of this QI project was the high engagement of the ambulatory nurses
and the clinical/ information management teams. The ambulatory nurses, information

43
management analysts, and the CMM project team brainstormed proposed interventions and
quickly designed, built, and implemented them within a couple of weeks. The ambulatory nurses
were remarkable in their ability to complete these ePAs even with high patient volumes and
staffing shortages. Having an engaged and educated staff, an organizational culture and
infrastructure to support innovation, and a quality improvement project with identified outcome
measures are all factors that support sustainability (Mortimer et al., 2018). Sustainability is a
critical part of any QI project, and not evaluating sustainability will result in leaders repeating
mistakes and diminishing return on value.
Assessing user satisfaction to inform optimization interventions may be a sustainable
practice for future informatics projects but will be dependent on whether the resource needs are
worth the return on value. User involvement surveys are useful tools for evaluating satisfaction
and utilization, but risks such as survey fatigue are of concern, especially in constrained resource
environments such as healthcare. Overall, this QI project is sustainable to scale to other health
informatics projects at the pediatric organization. The pediatric organization has the right
environment, with the project management infrastructure and support, a culture for excellence,
and an engaged workforce for long term sustainability of informatics QI projects.
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Literature Review Table
TITLE OF
ARTICLE

Retrospective
database analysis
of the impact of
prior authorization
for type 2 diabetes
medications on
health care costs in
a Medicare
Advantage
prescription drug
plan population.
(2013)

Impact of prior
authorization (PA)
of antiepileptic
drugs in children
with epilepsy
(2018)

AUTHORS

Bergeson,
Worley, Louder,
Ward, & Graham
(2013)

Wirrell,
Vanderwiel,
(2018).

RESEARCH
TYPE OF
LEVEL OF
QUESTION OR
DESCRIPTION
STUDY
EVIDENCE
AIM OF THE
OF SAMPLE
(DESIGN)
ARTICLE
Impact of Medication Prior Authorization on Clinical Outcomes
To examine the
Non-experimental Research-Level Pharmacy, medical
relationship
(quantitative)
III. High
and laboratory
between receiving
time dimensional
quality
claims data from
Type 2 diabetes
descriptive
4,101 Medicare
medication
retrospective
Advantage
requiring PA,
cohort
Prescription Drug
health care costs,
Plan members who
and subsequent
receive Type 2
treatment for type
Diabetes
2 diabetes.
medications
requiring PA.
Time period: Jan.1,
2008-June 30,
2009.

Assessed how
common
medications
requiring prior
authorization could
result in treatment
delay or missed
doses in children
with epilepsy.

Non-experimental
(quantitative)
time dimensional
descriptive
retrospective
cohort

Research-Level
III. High
quality

Parents of 462
children with
epilepsy surveyed,
164 survey
responses in this
single institution

OUTCOME
MEASURES

RESULTS / KEY
FINDINGS

Participants were
broken into 2
cohort groups,
those receiving PA
approval and those
denied approval..
Overall pharmacy
costs, overall
healthcare costs,
and whether
participantsmaintained therapy
were measured.

Overall healthcare and
pharmacy costs for those
who received PA
approval was lower and
statistically significant.
Those with approved
PAs also maintained
current therapy at a
higher rate.

Number of missed
doses of the antiepileptic
medications.
Number of patients
that had increased
seizures.

Relevant, current,
reliable primary source
and specific to the
chronic disease problem
statement.
Suggests health plans
consider impact of
utilization management
strategies on reducing
pharmacy costs along
with the broader
implications for
healthcare costs and
treatment patterns among
members.
Medication PA of antiepileptic drugs often
results in delays in
medication therapy with
negative impacts on
seizure control.
Relevant, current,
reliable primary source
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TITLE OF
ARTICLE

AUTHORS

Effect of a prior
authorization
process on
antiplatelet therapy
and outcomes in
patients prescribed
clopidogrel
following coronary
stenting (2006)

Ackman, Graham,
Hui, Tsuyuki .

PHP84 - Impact of
prior authorization
restrictions on
resource utilization
and costs in US
health plans: a
review of literature
(2014)

Shah, Tongbram,
Paly.

Treatment delays
associated with
prior authorization
for infusible
medications: a
cohort
study (2019)

Wallace, Harkness,
Fu, Stone, Choi,
Walensky.

RESEARCH
QUESTION OR
AIM OF THE
ARTICLE

TYPE OF
STUDY
(DESIGN)

LEVEL OF
EVIDENCE

To determine the
effect of a policy
change in
medication
coverage for
clopidogrel on
patients’ filling of
prescriptions and
outcomes
following stent
insertion.
A review of
published peerreviewed literature
was conducted to
evaluate the impact
of prior
authorizations,
restrictions on
resource
utilization, and
costs.

Non-experimental
(quantitative)
time dimensional
descriptive
retrospective
cohort

Research-Level
III. High
quality

Literature review

Non-ResearchLevel V High
quality

Examine the
effects prior
authorizations
(PA) requirements
have on patientoriented outcomes
with
rheumatologic
disorders.

Non-experimental
(quantitative)
retrospective
cohort

Research-Level
III. High
quality

DESCRIPTION
OF SAMPLE

Study sample of
112 patients over
the age of 65 years
who received an
intra-coronary
stent and were
prescribed the antiplatelet medication
clopidogrel.

OUTCOME
MEASURES
Number of patients
requiring
admission for
status epilepticus
Days between
order to pharmacy
fill.
Number of patients
who experienced a
myocardial
infarction and /or
required
revascularization
procedures.

Targeted review of
literature in
Medline resulted in
14 studies that met
inclusion criteria.

Resource
utilization and cost
of medications.

225 rheumatology
patients prescribed
biologic
medications in a
single academic
institution.

Number of days
between
medication order
and medication
infusion.

Clinical safety and
quality of life data
specific to the 14
studies.

Proportion of
denied PAs.
Number of days on
glucocorticoid
steroids while
awaiting infused
biologics.

RESULTS / KEY
FINDINGS
and specific to chronic
disease problem
statement.
Medication PA may
delay patient access to
necessary medications
resulting in significant
potential for negative
clinical consequences.
Relevant, NOT current,
reliable primary source.
Specific to chronic
disease problem
statement.
Medication PA
restrictions may result in
cost-savings, but patient
safety and quality of life
concerns must also be
evaluated while imposing
these restrictions.
Relevant, current,
reliable primary source
and specific to chronic
disease problem
statement.
Medication prior
authorizations are
associated with treatment
delays and denials, and
with greater
glucocorticoid exposure
Relevant, current,
reliable primary source
and specific to the
chronic disease problem
statement.
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TITLE OF
ARTICLE

AUTHORS

Examining the
prior authorization
process, patient
outcomes, and the
impact of a
pharmacy
intervention: A
single-center
review (2019)

Propatia, Flood,
Golbari, Patel,
Olbricht, Kimball,
Porter

RESEARCH
QUESTION OR
AIM OF THE
ARTICLE
Examine the effect
of a centralized
pharmacy
intervention on the
prior authorization
(PA) process and
the impact of PAs
on patient
outcomes in a
dermatology
practice.

TYPE OF
STUDY
(DESIGN)

LEVEL OF
EVIDENCE

Non-experimental
(quantitative)
time dimensional
descriptive
retrospective
cohort

Research-Level
III. High
quality

DESCRIPTION
OF SAMPLE

OUTCOME
MEASURES

Retrospective
review of all
prescriptions
requiring prior
authorizations in a
single academic
institution

Number of days
from prior
authorization
submittal to
approval decision.

Patients with approved
PAs had higher
likelihood of disease
improvement versus
those with denied PAs

Number of prior
authorization
denials.

Relevant, current,
reliable primary source
and specific to chronic
disease problem
statement.

Qualitative review
of disease
improvement post
medication
authorization.

RESULTS / KEY
FINDINGS

A centralized pharmacy
intervention is a costeffective measure
resulting in fewer delays
and improved PA
decision outcomes but
does not eliminate the
overall burden of PAs

Intervention Articles
Medication prior
authorization from
the providers
perspective: A
prospective
observational
study (2016)

Evaluation
frameworks for
nursing
informatics (2005)

Bhattacharjee,
Murcko, Fair,
Warholak

Currie

Objectives of this
study were to
identify, analyze,
and categorize the
issues associated
with the
medication PA
process from
provider practice
perspective

Study examines
strengths and
weaknesses of
published

Non-experimental
(qualitative)
ethnography

Literature review

Research-Level
III. Good
quality

Non Research
Level V, High
quality

29 prescribers, 8
practices from
April 13, 2015April 24, 2015

14 qualitative
evaluation
frameworks
reviewed and
categorized into 3

Direct observation
survey tool
captured PA
processing times at
every step of
process

Only 7 evaluation
frameworks met all
5 criteria. Of the
seven that met all 5
criteria each have

PA process for
medication used by
community providers is
in urgent need of
modernization. Pain
points identified in this
study could be alleviated
by implementing
medication electronic PA
(ePA solutions.
Relevant, current, small
data sample period,
includes chronic disease
patients
Provided a critique of a
comprehensive list of
evaluation frameworks
specific to healthcare
informatics project.
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TITLE OF
ARTICLE

AUTHORS

RESEARCH
QUESTION OR
AIM OF THE
ARTICLE
informatics
frameworks

TYPE OF
STUDY
(DESIGN)

LEVEL OF
EVIDENCE

The Triangle
Model for
evaluating the
effect of health
information
technology on
healthcare quality
and safety (2011))

Ancker, Kern,
Abramson,
Kaudral.

Illustrates the
Triangle model for
evaluating health
information
technology,
accommodating
both qualitative
and quantitative
evaluation
approaches with an
electronic
prescribing project

Case Report

Non Research
Level V, High
quality

Evaluating
informatics
applications—
clinical decision
support systems
(CDSS) literature
review (2001)

Kaplan

Literature review
focused on the
evaluation of
clinical decision
support systems
effect on patient
care

Literature review

Non Research
Level V, High
quality

DESCRIPTION
OF SAMPLE

OUTCOME
MEASURES

RESULTS / KEY
FINDINGS

groups. Each
framework was
critiqued based on
the following
criteria: context
centric, user
centric,
functionality
centric, recognizes
system
development
process and if
theory based
Used the Triangle
Model to evaluate
quality and safety
on the
implementation of
an electronic
prescribing
software.

strengths and
weaknesses based
on the project type
and environment

Article was relevant and
specific to the
intervention of healthcare
project evaluations, is
specific to the intended
users in healthcare but
not specific to electronic
medication PA.

The authors posit
that the triangle
model is most
appropriate for
summative
evaluations of
relatively mature
health IT systems
with good adoption
rates. The Triangle
model is not
intended to be a
model of diffusion
or adoption.
The quantitative
randomized
controlled trial
(RCT) was the
most frequently
used evaluation
approach but
qualitative
approaches are
increasing in use
more recently

Proposes a model for
health information
technology evaluation
which is theoretically
grounded in
Donabedian’s Theory.
Article is relevant and
specific to the proposed
intervention of healthcare
project evaluation, but
not specific to electronic
medication PA.

The authors
reviewed 27
studies reported in
35 papers on
evaluation
methods and study
desicn of CDSS

RCT studies are
excellent in
demonstrating whether
an intervention has a prespecified effect but these
study designs tell us little
regarding user adoption
and usability. The
authors suggest a
“plurality” of methods be
used in evaluating
informatics applications.
Article is relevant to the
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TITLE OF
ARTICLE

AUTHORS

RESEARCH
QUESTION OR
AIM OF THE
ARTICLE

TYPE OF
STUDY
(DESIGN)

LEVEL OF
EVIDENCE

DESCRIPTION
OF SAMPLE

A multi-level
usability
evaluation of
mobile health
applications: a case
study (2018)

Cho, Yen,
Dowding, Merrill,
Schnall

Aim is to report a
3 -tier
methodological
approach for
mobile health
application
usability
evaluation

Case report

Non Research
Level V, Good
quality

Authors present a
3 level method of
healthcare
informatics
application
evaluation. 1.Usertask 2. User-tasksystem 3. Usertask-systemenvironment.
Interventions were
mixed methods of
quantitative RCT’s
and qualitative
interviews.

Prior
Authorization and
Utilization
Management
Concepts in
Managed Care
Pharmacy (2019)

2018-2019
Academy of
Managed Care
Pharmacy
Professional
Practice
Committee
(AMCP)

Provide a
consensus
statement for the
effective prior
authorization
practices by
managed care
organizations.

Consensus
statement from
nationally
recognized
organization

Non research Level IV.
Good quality

Not applicable

OUTCOME
MEASURES

Participants in both
the intervention
and control rated
usability of the
application as
high. 15 themes
were identified
from the
qualitative
interviews. Of
these 15 themes,
the authors found
that the users felt
the app is useful,
the app is easy to
use, and that the
app would be
useful
communication
tool between the
patient and care
team.
Not applicable

RESULTS / KEY
FINDINGS
evaluation, intervention
proposed and is specific
to healthcare informatics
but is not specific to
electronic medication
PA. Article is outdated.
Author presents a
comprehensive
evaluation tool that is
specific to health
informatics mobile
applications. The
evaluation tool
incorporates end user
usability testing,
heuristic evaluation, a
survey and ethnography.
Though not specific to
electronic medication PA
applications, this could
translate well for the
evaluation intervention.
The article is recent.

The AMCP recommends
the following concepts to
ensure that patients
receive appropriate and
timely access to drugs,
devices, and other
therapeutic agents: (1)
patient safety and
appropriate medication
use, (2) clinical decision
making, (3) evidencebased review criteria, (4)
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TITLE OF
ARTICLE

Some Medicare
Part D
beneficiaries face
avoidable extra
steps that can
delay or prevent
access to
prescribed drugs.
(2018)

AUTHORS

Office of Inspector
General (OIG).
U.S. Department
of Health and
Human Services

RESEARCH
QUESTION OR
AIM OF THE
ARTICLE

Provide a
consensus
statement on
behalf of the OIG
offering
opportunities to
improve the prior
authorization
programs and
processes.

TYPE OF
STUDY
(DESIGN)

Consensus
statement from
government
organization
expert panel

LEVEL OF
EVIDENCE

Non research Level IV. High
quality

DESCRIPTION
OF SAMPLE

Analyzed 2017
annual
performance data
for 499 Medicare
Part D contracts

OUTCOME
MEASURES

Examined
pharmacy
rejections, denials,
appeals, and
overturned denials
for medications
requiring prior
authorization from
Medicare Part D
participants

RESULTS / KEY
FINDINGS
automated decision
support, (5) transparency
and advanced notice, (6)
emergency access, (7)
provider collaboration,
(8) need for timeliness
and avoiding disruptions
in therapy, and (9) costeffectiveness and value.
Key findings: 1.
Sponsors rejected
millions of prescriptions
that beneficiaries
tried to fill at
pharmacies, potentially
creating extra steps for
beneficiaries that could
have been avoided. 2.
Sponsors sometimes
inappropriately rejected
prescriptions that
beneficiaries tried to fill
at pharmacies 3.
Sponsors overturned 73
percent of drug coverage
denials that were
appealed, indicating that
some denials could have
been avoided
Key intervention
recommendations: 1.
Take additional steps to
improve electronic
communication to reduce
coverage denials and
pharmacy rejections.
2. Take action to reduce
inappropriate pharmacy
rejections and denials 3.
Provide beneficiaries
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TITLE OF
ARTICLE

Consensus
statement on
improving the
prior authorization
process (2019)

AUTHORS

American Medical
Association
(AMA)

RESEARCH
QUESTION OR
AIM OF THE
ARTICLE

Provide a
consensus
statement on
behalf of the AMA
offering
opportunities to
improve the prior
authorization
programs and
processes.

TYPE OF
STUDY
(DESIGN)

Consensus
statement from
nationally
recognized
organization

LEVEL OF
EVIDENCE

Non research Level IV.
High quality

DESCRIPTION
OF SAMPLE

2018 AMA
Physician survey:
29 question, web
survey December
2018. Sample of
1000 practicing
physicians, with
40% primary
care/60%
specialists,
currently
practicing more
than 20+ hours per
week and complete
PAs during a
typical week of
practice.

OUTCOME
MEASURES

Average wait time
for PA responses,
Care delays
associated with
PA, abandoned
treatment
associated with
PA, impact of PA
on clinical
outcomes,
physician
perspective on PA
burden, Change in
PA burden over
last 5 years

RESULTS / KEY
FINDINGS
with clear, easily
accessible information.
Relevant, current,
reliable primary source
Consensus statement
provides
recommendations for
interventions: 1.
Selective application of
prior authorization 2.
Prior Auth program
review and volume
adjustment 3.
Transparency and better
communication
regarding prior auth. 4.
Support continuity of
care. 5.Automation to
improve transparency
and efficiency.
Relevant, current,
reliable primary source
but not specific enough
to diabetes problem
statement.

57

Appendix B
Theoretical Models

Figure 1: Technology Acceptance Model diagram from Venkatesh, 2000.

Figure 2: Diffusion of Innovation diagram from Rogers, 2003.
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Appendix C
Kellogg Logic Model
RESOURCES/INPUTS

Ambulatory operations
and nursing leadership,
pharmacy, Information
Management (IM) and
technology (IT) leaders,
data analytics, and
clinical informatics
leaders.
Financial budget for
resource hours

Ambulatory nurses,
pharmacists, ordering
providers (physicians
and advanced practice
professionals),
ambulatory leadership.

Ambulatory Operations
and nursing leadership,
IM and IT leaders,
pharmacy, data
analytics, clinical
informatics, clinical and
organizational
development (COD) and
electronic health record
(EHR) training.

ACTIVITIES
Develop a
post IT project
summative evaluation
(clinical, operations,
financial) of the
electronic prior
authorization (ePA)
system
Develop
interdisciplinary
project steering team
Communicate results
from initial summative
evaluation including
user survey.
Select a validated
informatics user
adoption and
satisfaction survey.

Design and implement
an optimization plan
based off summative
evaluation.
Confirm and schedule
IT/IM, clinical
educators, EHR
trainers and cinical
informatics resource
for optimization
changes.

Initial

OUTPUTS
Targeted Group

Initial summative
evaluation of the
electronic ePA
application program
interface (API)

Ambulatory
operations and
nursing leadership,
IT and IM
leadership,
pharmacy.

Short Term
Outcomes
Initial evidence
based post IT project
summative
evaluation reported
to stakeholders by
June 7th, 2021

Build organization
structure to support
project team.

Validated informatics
user adoption and
satisfaction survey.

Ambulatory nurses
and providers.

Initial evidence
based validated user
survey administered
to 75% of identified
user community by
June 7th, 2021.

Optimization plan to
include operations,
EHR changes, and
EHR informatics
workflow changes.

Patients and families,
Ambulatory nurses
and providers.
Ambulatory
operations and
nursing leadership.

58% (5% higher than
industry benchmark)
of mediations
requiring PA are
approved by August
31st, 2021. (CO)

Confirmed schedule
of all resources for
optimization
Approved budget for
optimization.

OUTCOMES
Intermediate
Outcomes
Post IT project
summative
evaluation reported
to stakeholders 1year post
optimization by June
2022.

Subsequent (1 year
post) evidence based
validated user survey
administered to 75%
of identified user
community by June
2022.
3% improvement
year-to-year in first
submission PA
approval for 2 years
post optimization
(CO)
3% improvement
year-to-year of
medications
requiring prior
authorization

Long Term
Outcomes
Evidence
based
informatics
project
evaluation
completed
pre- and postevery
electronic
health records
(EHR)
project.

Evidence
based
validated user
surveys
completed
pre- and postevery EHR
project.
Improved
disease status
and chronic
disease
control; i.e.,
glycemic
control in
diabetes
patients,
decreased
seizures for
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RESOURCES/INPUTS
Financial budget for
resource hours and
education.

Ambulatory nursing
leadership, EHR
training, and COD
educators.

ACTIVITIES
Obtain approval for
optimization budget.
Communication of
optimization changes.

Initial

OUTPUTS
Targeted Group

Short Term
Outcomes

Communication plan
of optimization
changes.

Develop optimization
education and training

Optimization
education and training
plan. Attendance
sheet.

Ambulatory nurses
and providers.

Complete validated
user adoption and
satisfaction survey.

Survey released to
staff to complete.

Ambulatory nurses
and providers.

75% of users
complete
optimization
education. (PO)

Financial budget for
resource hours and
education.
Ambulatory operations
and nursing leaders, IM
and IT leaders,
pharmacy.
Financial Budget for
resource hours and chart
audits.

Chart audits of ePA
system usage.

OUTCOMES
Intermediate
Outcomes
approval within 48
hurs of order
submission for 2
years post
optimization. (CO)
2% reduction yearto-year in medication
order to medication
PA approval time for
2 years post
optimization. (CO).
Electronic
medication prior
authorization
education included in
Electronic Health
Record new hire
orientation training
by year 2 post
optimization (PO)

Electronic
medication PA
system user adoption
rate greater than 75%
post optimization
(PO).

Electronic
medication PA
system user adoption
rate greater than 80%
2 years post
optimization (PO).

Greater than 50%
response rate to an
electroni medication
PA post
implementation
evaluation user
survey post
optimization (PO)

Electronic
medication PA
system user
satisfaction rate
greater than 75% - 2
years post
optimization (PO)
Greater than 75%
response rate to an
electronic medication
PA post
implementation
evaluation user

Long Term
Outcomes
epileptic
patients.

New users
continue to
adopt the
electronic
medication
PA system at
a rate higher
than 80%.
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RESOURCES/INPUTS

ACTIVITIES

Initial

OUTPUTS
Targeted Group

Short Term
Outcomes

OUTCOMES
Intermediate
Outcomes
survey 2 years post
optimization (PO).

Long Term
Outcomes
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Appendix D
Gannt Timeline
Project: Reducing Delays for Medications Requiring Prior Authorization: A Post Health IT Project Summative Evaluation and Optimization
Timeframe
Activity
PLANNING
Research and develop informatics post implementation summative
evaluation tool
Identify sources for key performance data for summative evaluation
Determine key performance measures-clinical, operational, financial
and user (adoption and satisfaction)
Research and select a validated informatics implementation survey tool
Perform summative evaluation of electronic PA system of existing data
Communicate initial evaluation results to leadership and staff
Develop optimization plan based off summative evaluation
Develop resource and financial plan
Develop communication plan
Memorandum of understanding signed by organization
IMPLEMENTATION
Schedule resources and budget spending
Implement communication plan
Implement optimization based off initial summative evaluation
Perform post optimization summative evaluation
DATA COLLECTION
Collect existing electronic PA data for initial project evaluation
Collect key performance data for project evaluation post optimization
DATA ANALYSIS
Initial informatics post implementation summative evaluation prior to
optimization
Post optimization summative evaluation data analysis
DISSEMINATION

Oct
20’

Nov
20’

Dec20’

Jan
21’

Feb
21’

Mar
21’

Apr
21’

May
21’

Jun
21’

July
21’

Aug
21’

Sept
21’

Date
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Project: Reducing Delays for Medications Requiring Prior Authorization: A Post Health IT Project Summative Evaluation and Optimization
Timeframe
Activity
Communicate final report to executives and stakeholders
Decide whether to pursue article publishing
Final Report - May 2022

Oct
20’

Nov
20’

Dec20’

Jan
21’

Feb
21’

Mar
21’

Apr
21’

May
21’

Jun
21’

July
21’

Aug
21’

Sept
21’

Date
Fall
21’
Fall
21’
May
22’
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Appendix E
SWOT Analysis Table
Strengths
1. Well established multidisciplinary
diabetes clinic, workflows and
leadership
2. Oversight and supervision of nursing
and ancillary diabetes clinic staff
3. Access to data from our EHR,
specifically prescription ordering
timestamps
4. Ability to lead projects and changes in
the endocrine division and outpatient
clinics.
5. Chronic diseases such as diabetes
targeted in recent community health
needs assessment
Opportunities
1. New incoming division leadership looking
to increase research and evidence-based
practice changes.
2. Community health team investment is
working on food/nutrition and activity to
address type 2 diabetes in 2 specific
neighborhoods in Chicago.
3. Organization approved centralized med
prior auth team and electronic med prior
authorization system.

Weaknesses
1. Existing data had to be manually
captured. Not a lot of new data.
2. Do not have access to data at receiving
pharmacies
3. Diabetes team involved in many other
heavily resourced projects
4. New endocrine division leadership
currently transitioning

Threats
1. Project timeline for implementation of
electronic med prior authorization system
misaligned with scholarly project timeline
2. Other diabetes projects may be prioritized
higher for resources and support.
3. Resources for health IT project evaluation
and optimization are not guaranteed or
may not be available at the right time.
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Appendix F
Memorandum of Understanding
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Appendix G
User Involvement Survey
(Adapted from the Doll and Torkzadeh Survey, permission not required)
Question
Dimension

Scale

Does the system provide the information you
need

Content

5-Point Likert Scale

Are you satisfied with the accuracy of the
system
Do you consider the system to be reliable

Accuracy

5-Point Likert Scale

Accuracy

5-Point Likert Scale

Is the information clear

Format

5-Point Likert Scale

Are you satisfied with the layout of the output

Format

5-Point Likert Scale

Does the system provide up-to-date
information
Does the system provide updated info often
enough

Timeliness

5-Point Likert Scale

Timeliness

5-Point Likert Scale

Is the data in the system updated fast enough

Timeliness

5-Point Likert Scale

Is the system user friendly

Ease-of Use

5-Point Likert Scale

Is the system easy to use

Ease-of Use

5-Point Likert Scale

Is the system efficient

Ease-of Use

5-Point Likert Scale

Would you recommend the ePA system

Satisfaction

5-Point Likert Scale

Comments:

Open ended question

Free text

User Data Points:
•

How often do you use the ePA system per week? (Number entry)

•

How many years of experience as a registered nurse? (Number entry)

•

How many years of experience do you have completing medication prior authorizations?

•

What is your ambulatory specialty? (Drop down list)
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Appendix H
Pre- and Post-Optimization Survey Results: Free Text Comments Groupings
Subject

Survey Comment

Grouping

PRE-OPTIMIZATION SURVEY RESULTS—FREE TEXT COMMENTS GROUPINGS
When clinic notes are requested. It is difficult to upload. We have to print this out and upload.
Extremely time consuming. The EPIC needs an automatic attachment to upload clinic notes.
The prior authorization questions we get for ePAs are often not as specific as we get on cover my
meds. I find cover my meds website easier to use and easier to follow up on pending PA's. The layout
and tabs could be easier to use in the EPIC. However, it is nice to have the approval automatically
saved when done thru Epic
I would like to be able to do all PA's this way

Negative

Ease of Use

Epic/CMM is a beneficial tool for completing PA request. It is able to identify the patient's pharmacy
benefit manager and demographics which saves me time. Unfortunately as a member of the
centralized prior authorization team, I do not use this interface to complete request. The request are
attached to the provider's fax number and many times determinations are faxed instead of
uploading to Epic. It takes time to track down determination letters. Instead I will use the request
key already created and complete on CMM's website as the demographics are already included. In
CMM website I am able to change the fax number where I would like determination letter faxed.

Negative

Ease of Use

I do use cover my meds, but my concern with it when it declines it, I have to contact the insurance to
find out why, so that's an extra step. Last week I had a PA that required my talking to insurance and
issue is they wouldn't accept sweetener being used, and I couldn't find that out till I called insurance.
Cover my meds did not know. I actually prefer Meridian online as that's the easiest, and I also have
forms for numerous companies - CVS caremark, Optum Rx, Prime Therapeutics to use. Illinois
Medicaid is quick by phone when I'm in a rush to get a med approved. Things that are frustrating w/
cover my meds are when I don't have write insurance ID, don't have right dx code, and they cannot
help me where an insurance company can

Negative

Ease of Use
Ease of Use

Ease of Use

Neutral

Positive
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Subject
Ease of Use

Survey Comment

Grouping

This system is very difficult to follow.. there is no step to step process.. poor feedback on what item
is missing and often MCO groups prefer their firm, so this EPA is useless and often is double work.
Not efficient at all.

Negative

Ease of Use

Using this system is as clear as mud!

Negative

Accuracy

In theory, the system should be easier to use than going to the CMM website. However, it is not. The
pharmacy benefits are typically either wrong or not available.

Negative

Accuracy

Many authorizations are submitted and not needed, cannot locate patient

Negative

Accuracy

Specifically in neuromuscular, our medications are so specialty that it does sometimes trigger the
EPA but we have to do the medication through already established PA processes. It’s just another
thing that is in the way for these medications.
I often find that ePA requests authorizations that are already in place and not needed. It's difficult to
check the status on a submitted ePA. I prefer cover my meds or a paper form I can fax in.

Accuracy
Accuracy

Accuracy

Accuracy
Timeliness

Negative
Negative

PA initiated with several PA not actually needed, perhaps an system improvement for providers is
needed to PA's are not initiated when not needed, also when PA's are initiated in through Epic they
will not always come through under Epic in basket and results in RN needing to complete PA under "
orders only tab"
The ePA system is a great idea, but frequently ends up being more time consuming than using
CoverMyMeds. Issues include medications being flagged as requiring PAs that do not require PAs,
legal names in out system differing than what is on the insurance card, having difficulty and MANY
extra steps attaching documents and the supporting chart notes which result in denials and PA
resubmissions, PA requests for medications which already have existing PAs on file that are not due
to expire.
the ePA system generates Prior Authorizations that are NOT needed so it can be a huge time waster
as it is automatically generated. Also, attaching clinic notes is not clear.

Negative

I will usually call to initiate a PA and then complete the form that is sent to me, usually I will get an
answer while I am on the phone.

Negative

Negative

Negative
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Subject
Timeliness

Timeliness

Format
Format

Subject
Ease of Use

Ease of Use
Ease of Use
Ease of Use

Accuracy

Survey Comment
The integrated system does not provide updated info on a regular basis, and you are stuck waiting
for it to respond. the integrated system also expects, or needs a PA for generic meds that DO NOT
require a PA, and sometimes you have difficulty releasing the medication and moving on. That is a
waste of people's time
I do not use it very frequently therefore I probably am not efficient at it. My biggest complaint is that
may give the determination faster but then you still have to wait for the denial letter to be faxed
before you can continue. That is very frustrating
There should be an option to renew PA, it goes away after 3/4 days and the only option is to start a
PA the previous way via cover my meds online or by fax
The system is not user friendly and there is always just a large list of patients (have to open each
individually to see which provider follows each patient). Also, medications that are covered get stuck
in that Epic tab and families complain that we did not send the prescription.
POST-OPTIMIZATION SURVEY RESULTS—FREE TEXT COMMENTS GROUPINGS

Survey Comment

Grouping
Negative

Negative

Negative
Negative

Grouping

We already use covermymeds (portal), which is a much easier, user friendly EPA. The EPA does not
automatically update for all meds, nor does it provide authorization information to the department
to provide to the pharmacy/HUB. Meds are held up unless manually released. Prefer to continue
with on-line submission as this is efficient and easy.
1) When it’s denied there’s a delay in getting documentation from the insurance carrier 2) when
denied it doesn’t tell you why.
I do not use this feature in NICU Follow Up Clinic

Negative

I prefer to use cover my meds—with ePA I have no way of tracking the status or checking to see if a
PA has a response. It still prompts for PA on medications that should not need one (eg,
levothyroxine)
The system is always calling for a PA for Symbicort and for Medicaid, brand is covered without issue.
It is also very challenging to know which patients belong to which provider. I think some reeducation
about the system may be helpful once the updates are complete.

Negative

Negative
Neutral

Negative
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Subject
Accuracy
Format
Timeliness

Survey Comment
Often insurances and patients do not match, PA not needed, multiple attempts needed at EPA to
complete.
Since the upgrade I now do NOT have a PA detail button to attach a PDF. Therefore I have to submit
a PA on the external CMM Portal.
Unfortunately, others in my office can’t tell when I have started a PA, it also can’t be checked on
once it is started, it will just continue to say “waiting for payer response”, you can’t renew if it is
delayed. It is not a helpful app within epic.

Grouping
Negative
Negative
Negative
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Appendix I - Outcome Evaluation Table

Outcome
Initial evidence-based post
IT project summative
evaluation reported to
stakeholders by June 7th,
2021
Initial evidence based
validated user survey
completed by 75% of
identified user community
by June 7th, 2021.

58% (5% above industry
benchmark) of medications
requiring PA are approved
on first ePA submission by
August 31st, 2021.
75% of medications
requiring prior authorization
are submitted prospectively
by August 31st, 2021.
5% reduction in median ePA
turnaround time from
baseline data by August 31st,
2021.

Data Collection Instrument /Data
Summative report consisting of user satisfaction survey results
and median medication prior authorization (ePA) times
reported to stakeholders prior to optimization implementation

Instrument: Doll and Torkzadeh validated user informatics
satisfaction questionnaire administered by Information
Management manager to identify user community. This
informatics user satisfaction survey is broken out into 5
dimensions: content, accuracy, format, ease of use, and
timeliness.
Data: The validated survey is a 12 question Likert 7-Point Scale
questionnaire. The scores from this user satisfaction survey
may correlate to increased user adoption and reduced
medication prior authorization times.
Instrument: Electronic health record (EHR-Epic) and Surescripts
(vendor) electronic medication prior authorization (ePA)
reports. The Epic ePA reports can be retrieved ad hoc. The
Surescripts reports are published monthly.
Data: Quantitative data report with the following data
measures: time for ePA approval from order to approval, ePA
approval rates, % of ePAs that were approved on first
submission.

Analysis Goal
Report baseline information to
stakeholders prior to
optimization.
Identify opportunities to
optimize the ePA process.
Provide a baseline report of
user satisfaction and user
adoption prior to optimization

Provide a report of ePA
efficiency and effectiveness

Analytic Technique
Met/Unmet

Descriptive Statistics
will be used to measure
the percentage of users
that complete the
satisfaction survey.

Descriptive Statistics
will be used to measure
the mean, median, and
standard deviations of
the scores from the
ePA data from the EHR
and Surescripts.
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Outcome
75% of visits will have
pharmacy insurance benefits
verified by August 31st, 2021.
75% of users complete
optimization education by
July 1st, 2021.

ePA system user adoption
rate greater than 75% post
optimization by August 31st,
2021.
ePA system user satisfaction
rate greater than 50% post
optimization by August 31st,
2021.
Greater than 50% response
rate to an electronic
medication PA post
optimization user survey by
August 31st, 2021.

Data Collection Instrument /Data

Instrument: ePA users will be sent a one-page tip sheet
regarding the optimization changes with a requested email
reply whether education was competed.
Data: Microsoft Excel spreadsheet will be used to collect the
number of users who completed education divided by total
number of users that were sent the education tip sheet.
Instrument: Adapted Doll and Torkzadeh informatics user
satisfaction questionnaire administered by Information
Management manager to identified user community. This
informatics user satisfaction survey is broken out into 5
dimensions: content, accuracy, format, ease of use, and
timeliness and satisfaction.
Data: The validated survey is a 12 question Likert 7 Point Scale
questionnaire. The scores from this user satisfaction survey
may correlate to increased user adoption, increased ePA
system utilization and reduced medication prior authorization
times.

Analysis Goal

Analytic Technique

Ensure a high percentage of
users complete the
optimization education.

Descriptive Statistics
will be used to measure
the percentage of users
that completed the
optimization education.

Provide a report of user
satisfaction and user adoption
of the ePA system post to
optimization.

Descriptive Statistics
will be used to measure
the mean, median, and
standard deviations of
the scores from the
user informatics
satisfaction survey. Will
use inferential
statistical T Test
analysis of the
qualitative open-ended
comment question.
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Appendix J
Budget (2-3 Year)
Arnold Butiu - Scholarly Project 2-3 Year Budget

Yearly Totals:
Expense Category

$11,210.00

$6,536.70

$6,788.80

3 year Total Cost of Project

$24,535.50

Year 1

Year 2

Year 3

Staffing Salaries

$5,070.00

$309.00

$318.27

1st year salaries include project steering team. 4 hours per year
for Project Manager for year 2-3 + 3% increases per year.

Yearly Survey

$1,200.00

$309.00

$318.27

1st year includes initial survey implementation costs. 4 hours per
year Project Manager for year 2-3 + 3% increases per year.

Labor- IT/IM ePA

$4,000.00

$206.00

$212.18

1st year includes initial survey implementation costs . 4 hours per
year IT/IM Analyst labor for year 2-3 + 3% increases per year.

$0

$5,600.00

$5,824.00

1st year includes initial survey implementation costs. 4 hours
per year Project Manager

Administrative Supplies

$100.00

$20.00

$20.60

1st year includes project team implementation supplies, following
years 2-3 cover incidental supplies for survey with 3% increases
per year.

Labor- Data Analytics Reporting

$340.00

$41.20

$42.44

1st year includes initial report development, years 2-3 cover 1
hour of labor to maintain reports with 3% increases per year.

Labor- Training and Education

$500.00

$51.50

$53.05

1st year includes education/training of initial optimization, years
2-3 cover 1 hour of labor to maintain education materials with 3%
increases per year.

$11,210.00

$6,536.70

$6,788.80

$11,110.00

$6,516.70

$6,768.20

$100.00

$20.00

$20.60

IT EHR- ePA Interface Fees

Operating Expense Subtotal
In Kind
Total Operating Expense

Rationale

Majority of expenses is labor provided in-kind

3 year total $140.60
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Appendix K
Expense Report
Arnold Butiu-- Scholarly Project Expense Report

Dollar Value
Source of Expense

Type of Cost (variable/fixed)

Expense Description

In Kind Total

$11,110

Grand Total

Description of
Cost

Estimated
Volume

Cost per Unit
Total

Staffing- Project Steering Team (In Kind)
Project Manager
Senior Director for Digital Health
Chief Medical Information Officer
Nursing Informatics Director
Informatics Educator
Nursing Educator
Software Vendor Support (CoverMyMeds)
Certified Diabetes Educator Nurse

$5,070

Salary offset for
project team

$75
$125
$150
$75
$40
$50
$50
$50

Variable
Variable
Variable
Variable
Variable
Variable
Variable
Variable

User Survey Development and Implementation (In Kind)
Development and
implementation of
$75
validated user
Variable
Development of user satisfaction and
adoption and user
user adoption survey in Survey Monkey
satisfaction
tool
or Microsoft Forms
Information Management (IM)--Electronic Prior Authorization (ePA) Optimization (In Kind)
$50
Variable
Pharmacy benefits insurance improvements
Optimization changes
$50
Electronic prior authorization Epic EHR improvements
Variable
in Epic Electronic
Pharmacy prior authorization Epic EHR
improvements
Administrative Supplies and Support

Office supplies- printed materials, copying,
handouts

Health Record (EHR)

$50

Variable

Staffing salary
per hour

40
4
2
2
8
4
4
8

$3,000
$500
$300
$150
$320
$200
$200
$400
$1,200

Project
Manager
staffing salary
hours to build
user surveys

16

$1,200

30

$1,500

30

$1,500

20

$1,000

$4,000
IM Epic
Analyst salary
hours to
optimize ePA

$100

$50

Fixed

Office supply
costs through
hospital
vendor

$50

Fixed

Refreshments
to be provided
by hospital
catering

2

$80

Kickoff and project close
meetings

Meeting Refreshments

1

$50

1

$50

Data Analytics and Reporting (In Kind)

$340

Adjust existing Epic
EHR ePA Reports

$40

Variable

Reporting
specialist
hours to revise
existing
reports

New chart audit report
in Epic

$40

Variable

Reporting
specialist
hours to
create chart
audit report

4

$160

Adjust existing
CoverMyMeds Reports

$50

Variable

Vendor
support to
revise existing
reports

2

$100

Variable

Training Tip
Sheets on ePA
Optimization

8

$400

Fixed

One time cost
to possibly use
WeLearn to
distribute
education

1

$100

Epic ePA Report Adjustments

Chart Audits for ePA user adoption

CoverMyMeds Medication Dispense Reports

Training and Education (in Kind)
Develop EHR ePA Optimization Training
materials

$500
$50

Development and
distribution of training
materials
$100

Use of electronic education system
(WeLearn)

$11,210
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Appendix L
Statement of Operations

Statement of Operations
Operating Income (All In Kind)

Arnold Butiu

Revenue Total
Source (ALL IN KIND)
Labor-Project Manager and
Project Steering Team
Labor- IT/IM

Description
Project labor for steering team
members and project manager
Project labor from IT/IM team

Labor-Survey Development
Organization

Project Steering Team Labor
Labor- IT/IM ePA

$

340.00

Project labor from EHR training team $

500.00

Project management labor to
develop and implement survey

$
Administrative supplies and space $

Survey Development
IT EHR- ePA Interface Fees
Administrative Supplies

$

Description
Project labor for steering team
members and project manager
Project labor from IT/IM team

1,200.00
100.00

11,210.00
Amount

$

5,070.00

$
$

4,000.00
340.00

Project labor from EHR training team $
Project management labor to
$
develop and implement survey
$
Administrative supplies and space $

500.00

Labor- Data Analytics Reporting Project labor from data analytics
Labor- Training and Education

Amount
5,070.00
4,000.00

Expenses Total
Expenses

11,210.00

$
$

Labor-Data Analytics Reporting Project labor from data analytics
Labor- Training and Education

$

1,200.00
100.00
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Appendix M
Optimization Intervention: Medications Excluded from ePA
ACETAMINOPHEN 160 MG/5 ML ORAL SUSPENSION [9230]
ALCOHOL SWABS [100655]
CALCIUM CARBONATE 200 MG CALCIUM (500 MG) CHEWABLE TABLET [18196]
CALCIUM CARBONATE 500 MG CALCIUM (1,250 MG) TABLET [1447]
DIPHENHYDRAMINE 12.5 MG/5 ML ORAL ELIXIR [2760]
DIPHENHYDRAMINE 12.5 MG/5 ML ORAL LIQUID [13821]
DIPHENHYDRAMINE 25 MG CAPSULE [2758]
DIPHENHYDRAMINE 25 MG TABLET [2754]
FERROUS SULFATE 325 MG (65 MG IRON) TABLET [3433]
IBUPROFEN 100 MG/5 ML ORAL SUSPENSION [11343]
SODIUM BICARBONATE 650 MG TABLET [21635]
CLINDAMYCIN PHOSPHATE 1 % TOPICAL SWAB [35060]
ATENOLOL 25 MG TABLET [793]
CIMETIDINE 400 MG TABLET [10673]
TRIAMCINOLONE ACETONIDE 0.1 % TOPICAL OINTMENT [9037]
GUANFACINE 1 MG TABLET [11243]
MINOCYCLINE 100 MG CAPSULE [5702]
KETOCONAZOLE 2 % TOPICAL CREAM [11473]
DOXYCYCLINE HYCLATE 100 MG TABLET,DELAYED RELEASE [142580]
CLINDAMYCIN 1 % LOTION [21703]
FLUOCINOLONE 0.01 % TOPICAL SOLUTION [3565]
DIVALPROEX 125 MG CAPSULE,DELAYED RELEASE SPRINKLE [104797]
MUPIROCIN 2 % TOPICAL OINTMENT [18755]
PROPRANOLOL 10 MG TABLET [7421]
PREDNISOLONE SODIUM PHOSPHATE 15 MG/5 ML (3 MG/ML) ORAL SOLUTION [34857]
HYDROXYZINE HCL 10 MG/5 ML ORAL SOLUTION [4248]
ALCLOMETASONE 0.05 % TOPICAL OINTMENT [10010]
SULFASALAZINE 500 MG TABLET [8429]
NAPROXEN SODIUM 550 MG TABLET [94625]
MIDODRINE 2.5 MG TABLET [11725]
FAMOTIDINE 40 MG TABLET [83213]
KETOROLAC 10 MG TABLET [36708]
LEVETIRACETAM 100 MG/ML ORAL SOLUTION [130502]
PROPRANOLOL 40 MG TABLET [91137]
ETODOLAC 300 MG CAPSULE [11088]
AMOXICILLIN 600 MG-POTASSIUM CLAVULANATE 42.9 MG/5 ML ORAL SUSPENSION [33882]
BUMETANIDE 1 MG TABLET [99832]
MULTIVITAMIN AND MINERALS NO.11-FOLIC ACID 5 MG TABLET [193887]
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Appendix N
Optimization Intervention: Matching Logic Changes
Patient Validation Failures Prior to Intervention 3/11/21-6/4/21

Optimization Change- 6/4/21 Patient Matching Validation with Pharmacy Benefits

Validation Screen Prior to Optimization Intervention
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Appendix O
Optimization Intervention: Attaching Documentation to an ePA Communication
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Appendix P
Optimization Survey Demographics
Total of 57 Pre-Optimization responses out of the 194 surveys sent out.
Years’ Experience
RN
Mean
Median
Mode
Standard Deviation
Sample Variance
Kurtosis
Skewness
Minimum
Maximum
Sum
Count

16.0
10
5
12.1
145.7
-0.58
0.80
2
46
912.35
57

Years’ ExperiencePA

Frequency PA /
Week

5.7
4
6
5.8
33.5
2.59
1.70
0
25
324.4
57

2.0
1.5
0
2.0
4.0
3.15
1.49
0
10
111
56

Total of 16 Post Optimization Survey Responses out of 194 Sent Out

Mean
Median
Mode
Standard Deviation
Sample Variance
Kurtosis
Skewness
Minimum
Maximum
Sum
Count

Years’ Experience
Years’ ExperienceFrequency PA /
RN
PA
Week
18.9
6.6
7.5
17.5
5
2.5
5
5
0
12.2
6.5
15.3
148.7
41.6
233.6
-1.23
0.56
10.30
0.34
1.26
3.12
4
0
0
40
20
60
302
106.3
121
16
16
16

82
Appendix Q
User Involvement Likert Score Summary and Net Promotor Score (NPS)

Mean Likert Score (1-5)

User Involvement Pre and Post Interventions
3.50
3.00
2.50

3.06
2.88

2.68
2.44

2.72

2.932.94

2.832.69

2.85
2.38

2.19

2.82
2.31

2.81
2.53

2.702.81

2.81
2.63

2.00
1.50
1.00
0.50
0.00
Does the
Are you
Do you
Is the
Are you
Does the
Does the
Is the data in Is the system Is the system
system
satisfied with consider the information satisfied with
system
system
the system easy to use?
efficient?
provide the the accuracy system to be
clear?
the layout of provide up-toprovide
user friendly?
information of the system? reliable?
the output?
date
updated info
you need?
information? often enough?

User Involvement Survey Questions

Pre-Intervention

Pre

Post

Post Intervention
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Appendix R
User Involvement Survey Responses by Specialty

User Survey Responses by Specialty
8

Number of Responses

7
6
5
4

3
2
1
0

Specialties

Pre

Post
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Appendix S
ePA Volumes and Turnaround Times Pre Optimization

85
Appendix T
ePA Volumes and Turnaround Times Post Optimization

